Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dave Mott
AddedMar 31, 2024
UpdatedMay 31, 2026
Dave Mott

Dave Mott

Board Member, BioHealth Innovation

CrunchbaseLinkedIn

Dave Mott's Career

BioHealth Innovation
BioHealth Innovation

Rockville, MD, US

Board Member· Board
Ardelyx
Ardelyx

Fremont, CA, US

Board Member· Board
Mersana Therapeutics
Mersana Therapeutics

Cambridge, MA, US

Board Member· Board
Novavax
Novavax

Gaithersburg, MD, US

Board Member· Board
Tiburio Therapeutics
Tiburio Therapeutics

Cambridge, MA, US

Board Member· Board
XTuit Pharmaceuticals
XTuit Pharmaceuticals

Waltham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dave Mott's Career

BioHealth Innovation
BioHealth Innovation
222011Rockville, MD, US
Board Member· Board

Leadership at BioHealth Innovation

Joel S. MarcusJoel S. MarcusBoard Member
Jarrod BorkatJarrod BorkatBoard Member
Anne LindbladAnne LindbladBoard Member
Ashish KulkarniAshish KulkarniBoard Member
Ronald J. DanielsRonald J. DanielsBoard Member
Rich BendisRich BendisFounder
Ardelyx
Ardelyx
Public$471.4M1332007Fremont, CA, US
Board Member· Board

Leadership at Ardelyx

Jan LundbergJan LundbergBoard Member
Peter G. SchultzPeter G. SchultzCo-Founder
Rick RodgersRick RodgersBoard Member
Michael RaabMichael RaabBoard Member
Onaiza Cadoret-ManierOnaiza Cadoret-ManierBoard Member
Geoffrey A. BlockGeoffrey A. BlockBoard Member

Similar to Ardelyx

Elcelyx TherapeuticsElcelyx TherapeuticsSan Diego, CA, USPharmaceuticalsest. 2010Elcelyx TherapeuticsSan Diego, CA, US · est. 2010

Elcelyx Therapeutics develops nutrient-based solutions for weight management and metabolic disorders.

Series E · $96.8M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
Mersana Therapeutics
Mersana Therapeutics
Public$655.6M2282001Cambridge, MA, US
Board Member· Board

Leadership at Mersana Therapeutics

Anna ProtopapasAnna ProtopapasBoard Member
Martin HuberMartin HuberBoard Member
K. Dane WittrupK. Dane WittrupBoard Member
Willard DereWillard DereBoard Member
C. Boyd ClarkeC. Boyd ClarkeBoard Member
Novavax
Novavax

Gaithersburg, MD, US

Board Member· Board
Tiburio Therapeutics
Tiburio Therapeutics
Public$31M92018Cambridge, MA, US
Board Member· Board

Leadership at Tiburio Therapeutics

James McArthurJames McArthurCo-Founder
Mette Kirstine AggerMette Kirstine AggerBoard Member
Chris AdamsChris AdamsCo-Founder
Sara NayeemSara NayeemBoard Member
Michael CullerMichael CullerBoard Member
XTuit Pharmaceuticals
XTuit Pharmaceuticals
Series A$26M302011Waltham, MA, US
Board Member· Board

Leadership at XTuit Pharmaceuticals

Alan CraneAlan CraneCEO
Rakesh K. JainRakesh K. JainFounder

Similar to XTuit Pharmaceuticals

Novita PharmaceuticalsNovita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7
Xios TherapeuticsXios TherapeuticsBoston, MA, USTherapeuticsest. 2015Xios TherapeuticsBoston, MA, US · est. 2015

Xios Therapeutics: Innovating small molecule therapeutics for enhanced immuno-oncology treatments.

Pre-Seed · $7M30
XentriaXentriaChicago, IL, USBiopharmaceuticals, Therapeuticsest. 2020XentriaChicago, IL, US · est. 2020

Xentria: Innovating cost-effective bio-pharmaceutical solutions for rare diseases and oncological conditions.

Series B · $25M13
Thetis PharmaceuticalsThetis PharmaceuticalsRidgefield, CT, USDrug Developmentest. 2011Thetis PharmaceuticalsRidgefield, CT, US · est. 2011

Thetis Pharmaceuticals: Specializing in cardio-metabolic, cancer, and autoimmune disease treatments.

Series A · $22.9M30

Dave Mott's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Dave Mott

Thomas MeierThomas MeierBoard Member · VisgenxDouglas FallerDouglas FallerBoard Member · Viracta TherapeuticsDan LynchDan LynchBoard Member · 2seventy bioScott MorrisonScott MorrisonBoard Member · Zai LabRob WillsRob WillsBoard Member · CymaBay Therapeutics